Teva's UZEDY Linked To Fewer Emergency Visits And Lower Healthcare Costs In Real-World Study

Oppenheimer initiated coverage of Viatris (VTRS) and Teva Pharmaceutical (TEVA) with Outperform ratings. Viatris has a $25 price target (~46% upside), and Teva has a $50 target (~27% upside).

Mayer Brown advised underwriters on Teva Pharmaceutical's $4.9 billion senior notes offering, which closed today. The firm's team included partners David Becker, Rob Mathews, and Ben Bierwirth, who recently joined Mayer Brown and have previously worked with Teva.

Teva presented new data on Olanzapine LAI and UZEDY® at Psych Congress 2026. Olanzapine LAI, in Phase 3 trials, showed 56% stabilization and 4% relapse rate among stabilized participants. UZEDY® data indicated better treatment continuity and lower healthcare costs. Olanzapine LAI awaits FDA decision in Q4 2026. Both treatments use Medincell's BEPO® technology.

Teva presented new data from its phase 3 SOLARIS study on olanzapine LAI, showing 56% of participants achieved clinical stabilization. The FDA decision on the treatment is expected in Q4 2026. Teva submitted its marketing application in December 2025, accepted by the FDA in February 2026.

Teva Pharmaceuticals presented real-world data showing UZEDY (risperidone) outperforms other treatments in schizophrenia, reducing emergency care and healthcare costs. The study found UZEDY patients had fewer ED visits and hospitalizations, with $1,036.70 monthly savings per patient. Teva highlighted UZEDY's role in improving treatment continuity and lowering healthcare resource utilization.

Teva Pharmaceuticals presented post hoc data from the SOLARIS Phase 3 trial for TEV-'749, a once-monthly subcutaneous injectable olanzapine treatment for schizophrenia. Over half of participants achieved stabilization, and 21% met remission criteria. The data were presented at Psych Congress 2026. Teva anticipates an FDA decision on TEV-'749 in Q4 2026.